Amphastar Pharmaceuticals, Inc.

AMPH Healthcare Drug Manufacturers Specialty & Generic

Amphastar Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $719.9 million, down 1.65% from fiscal 2024. In the quarter to June 2026, revenue grew 5.44%, EPS grew 4.55%, free cash flow grew 87.6% and total debt was flat, each against the same quarter a year earlier.

25.87 0.55 −2.08%
Market cap
$1.1B
P/E
14.9×
Fwd P/E
14.7×
Dividend yield
—
F-score
6/9
Altman Z
2.54
Beneish M
−2.57
Dividend safety
n/a

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Revenue
183.90 171.17 183.11 191.84

+8 more quarters

Revenue Growth
5.44% 0.38% (1.83%) 0.33%
Gross Profit
93.47 70.32 85.67 98.65
Operating Income
39.73 13.63 35.61 25.32
EBT
38.54 10.05 31.91 21.51
Income after Tax
30.35 6.42 24.43 17.35
Net Income Common
30.35 6.42 24.43 17.35
EPS (Diluted)
0.67 0.14 0.51 0.37
Shares (Diluted, Weighted)
44.23 46.46 48.22 47.68
Gross Margin
50.83% 41.08% 46.79% 51.42%
EBIT Margin
21.60% 7.96% 19.45% 13.20%
Net Profit Margin
16.50% 3.75% 13.34% 9.04%
EBITDA
54.92 28.74 50.81 40.33
EBIT
39.73 13.63 35.61 25.32

Show all line items

In millions of $ except per-share values · columns are period end dates